Skip to main content

Table 1 Clinical data and laboratory results in the patients of group 1 and controls

From: Increased incidence of precocious and accelerated puberty in females during and after the Italian lockdown for the coronavirus 2019 (COVID-19) pandemic

Variable   Group 1 Previous 5 yearsa P
Population number 37 89
Chronological age at B2 (as referred by parents or family pediatrician) 6.86 ± 0.61 7.22 ± 0.48 p < 0.005
Chronological age at diagnosis (yr) 7.11 ± 0.72 7.53 ± 0.50 p < 0.0005
Time from B2 to diagnosis (months) 3.1 ± 0.9 3.0 ± 0.8 P = NS
Height, SDS 0.84 ± 1.32 0.79 ± 1.44 P = NS
BMI, SDS 0.83 ± 0.91 0.68 ± 0.88 P = NS
Tanner stage at diagnosis (percentage)
 II 43.8 55.5  
 III 53,1 38.8 p < 0.05
 IV 3.1 5.4  
 V  
Bone age (yr) 9.40 ± 1.10 9.60 ± 1.20 p = NS
Bone age minus chronological age (yr) 2.29 ± 0.38 2.07 ± 0.70 P = NS
Basal LH, IU/L 1.2 ± 0.7 0.8 ± 0.6 p < 0.005
Basal FHS, IU/L 1.9 ± 1.7 2.2 ± 1.3 p = NS
Peak LH at GnRH stimulation, IU/L 11.9 ± 4.2 9.4 ± 4.0 p < 0.005
Basal estradiol (females only), pmol/L 129.9 ± 18.7 117.6 ± 19.2 p < 0.005
Uterine length, cm 4.42 ± 0.43 3.99 ± 0.47 p < 0.0005
Ovarian volume, cm3 3.32 ± 0.42 2.83 ± 0.46 p < 0.0005
Electronic device use (h) 3.9 ± 1.5
  1. a= mean/yr. BA bone age, CA chronological age, SDS standard deviation score, BMI body mass index, LH luteinizing hormone, FSH follicle-stimulating hormone, GnRH gonadotropin releasing hormone test